LexaGene’s Beta Prototype Exceeds Expectations During Testing at Massachusetts Veterinary Referral Hospital

, ,

98.2% Concordant with Reference Laboratory Generated Data

BEVERLY, Mass., July 10, 2019 (GLOBE NEWSWIRE) — LexaGene Holdings, Inc., (OTCQB:LXXGFTSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for rapid pathogen detection and other molecular markers, announced today the test results from its first beta prototype placed at the Massachusetts Veterinary Referral Hospital (Mass Vet) in Woburn, MA. Mass Vet is one of 24 hospitals owned and operated by Ethos Veterinary Health.

LexaGene’s test results were found to be >98% concordant with reference laboratory generated data. On average, four samples were processed per day, with infections caused by E. coli, Proteus, and Staphylococcus. During the study, the LexaGene test results correctly confirmed that 56% of the animals tested did not need antibiotics.

For the beta test trial, veterinarians at Mass Vet used LexaGene’s genetic analyzer to determine the cause of an infection and whether antibiotic resistance factors were present that could influence therapy decisions. They focused on processing canine and feline urine samples, but were given the opportunity to load other sample types onto the instrument such as swabs from surgical incisions, cervical swellings, and neck and chest wounds.

Dr. Sam Stewart DVM, DACVECC, Commercialization Scientist Fellow at Ethos Veterinary Health reports, “LexaGene’s analyzer is really going to be a game changer. Our team’s enthusiasm for this technology has been so overwhelming, we’ve asked LexaGene to allow some of our other hospitals to beta test the technology.” Video testimonials from the veterinary team can be viewed here.

“Emergency veterinarians are frustrated that there are no easy-to-use instruments to rapidly and accurately detect infectious diseases inside the hospital. This is a problem, as there are many conditions and diseases that may or may not be caused by an infectious organism,” said Dr. Jack Regan, CEO and Founder of LexaGene. “For example, the symptom of incontinence in a dog could be due to a urinary tract infection (UTI), bladder cancer, kidney or bladder stones, diabetes, Cushing’s disease, prostate gland disease, and relative estrogen withdrawal.”

Due to the difficulty of diagnosing a UTI on symptoms alone, only ~17.5% of urine samples submitted for reference laboratory testing come back as positive for at least one bacterial isolate.1

“In the absence of rapid diagnostics, veterinarians currently treat animals empirically with antibiotics based on symptoms. The cost of a two-week antibiotic course is roughly $200 depending on the size of the animal and the chosen therapy. If the statistics of this beta trial remain consistent for an entire year, we would predict >$150K could be unnecessarily spent on antibiotics across all the dogs and cats seen at Mass Vet during the year,” said Dr. Jack Regan, CEO and Founder of LexaGene.

The practice of prescribing antibiotics without certainty regarding the cause of symptoms can lead to antibiotic resistant strains of bacteria.2 Many of these strains are now resistant to multiple antibiotics (i.e. superbugs).3 In-hospital, rapid and accurate diagnostics are needed to improve more responsible antibiotic use in veterinary practice.

“Our team has been thrilled to have the opportunity to use LexaGene’s beta prototype, which returns results in about one hour versus three or more days for reference laboratory generated tests. Having this information so quickly allows us to improve the quality of care – which is our highest goal. We look forward to continuing our work with LexaGene to conduct further validation studies, publish a peer-reviewed manuscript, and help bring this product to market,” said Dr. Chand Khanna DVM, PhD, DACVIM (Onc), DACVP (Hon), Chief Science Officer of Ethos Veterinary Health and President of Ethos Discovery.

To be added to the LexaGene email distribution list, please subscribe on the Company website.

  1. Hall et al., Prevalence and antimicrobial resistance of canine urinary tract pathogens. Veterinary Record 2013.
  2. Normand et al., Trends of antimicrobial resistance in bacterial isolates from a small animal referral hospital. Veterinary Record 2000.
  3. Shao-Kuang et al., Antimicrobial resistance of Escherichia coli isolates from canine urinary tract infections J Vet Med Sci. 2015.

About LexaGene Holdings Inc.
LexaGene is a biotechnology company that develops genetic analyzers for pathogen detection and other molecular markers for on-site rapid testing in veterinary diagnostics, food safety and for use in open-access markets such as clinical research, agricultural testing and biodefense. End-users simply need to collect a sample, load it onto the instrument with a sample preparation cartridge, and press ‘go’. The LX Analyzer delivers excellent sensitivity, specificity, and breadth of detection and can process multiple samples at a time, in an on-demand fashion, returning results in about 1 hour. The unique open-access feature is designed for custom testing so that end-users can load their own real-time PCR assays onto the instrument to target any genetic target of interest.

LMU recognizes Ethos Veterinary Health and Mass Vet as Distinguished Clinical Affiliate

, ,

This article was originally published in the Citizen Tribune,  

Lincoln Memorial University-College of Veterinary Medicine (LMU-CVM) recognized Ethos Veterinary Health and the Massachusetts Veterinary Referral Hospital (Mass Vet), with the Distinguished Clinical Affiliate Award in recognition of the vital role the clinical partner played in preparing LMU-CVM graduates. Dr. Beth Eisenberg, veterinary criticalist for Ethos Veterinary Health and a veterinarian for Mass Vet, accepted the award at the LMU-CVM Commencement Ceremony on May 18 in Harrogate, Tennessee.

“With our distributive clinical model, we’ve been honored to work with many outstanding veterinarians and veterinary practices,” said LMU-CVM Vice President and Dean Jason Johnson. “Ethos prioritizes education, and we are proud of our partnership with this outstanding organization.”

Ethos owns and operates several practices throughout the United States including Mass Vet, located in Woburn, Massachusetts. Over the last two years, Mass Vet has provided 31 four-week rotations of exceptional clinical and educational experiences for 17 LMU veterinary medicine students. The students who have rotated through Mass Vet rated the experience at the top of all clinical affiliate experiences offered, and students highly recommend this program to future classes.Eisenberg provided the leadership to establish and oversee the Ethos Mass Vet LMU-CVM clinical partnership. She is part of Ethos learning and development team and is a diplomat of the American College of Veterinary Emergency and Critical Care.

“Dr. Eisenberg has shown a personal keen interest in the growth and learning of our students, and always welcomes our students to her practice,” said Johnson. “She and her Mass Vet associates have done a wonderful job challenging, educating and preparing each student on their clinical journey and for life post-graduation.”

LMU-CVM’s hybrid distributed community-based educational model allows premier practices and institutions to participate in the education of future graduates. Well-qualified fourth-year veterinary students rotate through select, high-quality clinical affiliate locations where they obtain real-world learning experiences from highly qualified veterinarians. It allows for a mutually beneficial collaborative partnership between the veterinary college and community professionals.

Read the article on the Citizen Tribune

Continued Growth for Ethos Veterinary Health

, ,

Ethos Veterinary Health Announces Continued Growth With The Addition of Two Hospital Groups

WOBURN, Mass., June 25, 2019 /PRNewswire:  Ethos Veterinary Health (Ethos), a leading independent veterinary health company, today announced the addition of two hospital groups: Wisconsin Veterinary Referral Center (WVRC), with three locations in Wisconsin, and Pet Emergency & Specialty Center of Marin (PESCM), located in San Rafael, Calif. The two entities substantially add to Ethos’ hospital network. WVRC extends Ethos’ Midwest footprint into Southern Wisconsin, and PESCM adds to Ethos’ existing presence in Northern California.

“We are excited to have these culturally aligned, successful teams join Ethos. The addition of WVRC and PESCM allows us to expand our network and the patient-focused medical care we believe in,” said Ames Prentiss, CEO of Ethos. “Both of these practices are well-established, professionally managed and highly respected in the industry.”

For WVRC and PESCM, joining Ethos means being able to take advantage of systems and programs they may not have had access to before.

“PESCM is excited to join an organization that honors and perpetuates our practice legacy while giving our team access to VetBloom, an enhanced educational and training platform, as well as a conduit for talent acquisition and proven best practices in the emergency/specialty space,” said Chris Rodi, DVM, Managing Partner at PESCM.

John Beltz, DVM, co-owner and Hospital Administrator of WVRC, added, “Dr. Jeff Meinen and I have known the Ethos team for many years, and we have a high degree of respect and confidence in their goals and mission. We chose to partner with and are glad to be part of Ethos as they strive to maintain the same high quality and ethical veterinary care we provide, while allowing us to leverage their size and scale for group efforts. Their commitment to the veterinary ethos is demonstrated not only in their words, but in their organizational structure, decision-making and actions.”

WVRC and PESCM also add to Ethos’ already extensive caseload. Over 300,000 patients are treated annually in Ethos hospitals. This allows for large clinical trials that generate data quickly, which in turn helps scale scientific innovation, an important priority for Ethos. This priority has seen significant momentum in 2019 with the completion of the CHAMP (Canine Hemangiosarcoma Molecular Profiling) Study – the first-ever, nationwide, multicenter, prospective study of Canine Splenic Hemangiosarcoma. In addition, the development of the ePARR test, a highly accurate test for the diagnosis of canine lymphoma, was announced in the second quarter of this year.

“Adding hospitals that share our vision of advancing veterinary medicine is a key focus for Ethos over the coming years,” said Brian Cassell, DVM, Chief Strategy Officer of Ethos. “We welcome the opportunity to speak with interested hospitals.”

# # #

For more info please contact info@ethosvet.com.

About Ethos Veterinary Health
Ethos is a veterinary health company with hospitals across the U.S. providing advanced medical care for pets. Our approach includes a focus on transformative science, continuous learning and growth for team members, and collaboration. For more information, visit ethosvet.com.

MEDIA CONTACT:
Nadja Torling
ntorling@ethosvet.com
720-722-3418

Bulger Veterinary Hospital Relocates to New, State-of-The-Art Facility Enhancing its Ability to Care for Pets

,

Lawrence, Mass. — June 12, 2019  – Bulger Veterinary Hospital will move to its new location at the former Showcase Cinema site in Lawrence, Massachusetts, located at 141 Winthrop Avenue in Lawrence, MA  the last week of June. The move brings the highly recognized 60-plus year-old Bulger Veterinary Hospital 2 miles, from neighboring North Andover to Lawrence, creating an exceptional facility for veterinary care. The 17,000 square foot state-of-the-art hospital will feature five surgery suites, more than twice as many exam rooms (20 in total) as the former hospital, a new 64-slice CT scanner, several waiting rooms including a dedicated waiting room for cats, and a larger emergency facility.

Services will continue to include primary veterinary care, 24/7 emergency and critical care (365 days a year), surgery, cardiology, internal medicine, ophthalmology, acupuncture, an exotics team and more.

“We are excited to offer such a remarkable facility with advanced medical care to the pets we love as our own family members,” said Steve Isherwood, Hospital Director. “I’ve been bringing my own pets here with my family since I was a child” he said.

Ames Prentiss, CEO of Ethos Veterinary Health, said “We are grateful to have the opportunity to expand our business into the city of Lawrence and become part of the community.  The Mayor and the City have been so supportive in our efforts and we are thankful for their encouragement.” Prentiss, an Andover native whose father, John K. Prentiss, DVM, purchased Bulger Veterinary Hospital in 1979, added, “We are proud of our history of high quality veterinary care for pet owners in the Merrimack Valley and are enthusiastic for the future in our new home.”

With the little over one-year construction now complete, Bulger’s North Andover location will close. All current 105 employees will move to the new location and the workforce could grow by another 15 people as new services are added.

“I want to congratulate Ames and his team on the opening of their new, state of the art veterinary hospital,” said Mayor Dan Rivera. “I also want to thank them for bringing their business into Lawrence and transforming a site that sat vacant for far too long and turned it into a premier site that will improve the quality of life for our community for years to come. Large scale development projects like this are what help our community continue to thrive and I am thrilled to have Bulger Veterinary Hospital – the premier animal hospital of the Merrimack Valley – make Lawrence its home.”

STAY TUNED: A Ribbon cutting ceremony and grand opening event is scheduled for September 25, 2019!

# # #

About Ethos Veterinary Health

Ethos is a veterinary health company with hospitals across the U.S. providing advanced medical care for pets. Our approach includes a focus on transformative science, continuous learning and growth for team members and collaboration. For more information, visit ethosvet.com.

 

LexaGene Places its First Beta Prototype into Massachusetts Veterinary Referral Hospital

, , ,

Source: LexaGene Holdings Inc

BEVERLY, Mass., June 05, 2019 (GLOBE NEWSWIRE) — LexaGene Holdings, Inc., (OTCQB: LXXGFTSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for rapid pathogen detection and other molecular markers, announced today that it has placed its first beta prototype into Massachusetts Veterinary Referral Hospital (Mass Vet) in Woburn, MA.  Mass Vet is one of 24 hospitals owned and operated by Ethos Veterinary Health.

“This placement marks a very significant milestone for the Company and for the diagnostics industry.  We have generated a long list of interested users who want to test our technology.  From this list, we selected Mass Vet to be our first site due to their reputation for being pioneers and thought leaders in veterinary medicine.  The doctors at Mass Vet are eager to test our cutting-edge technology to provide the best possible treatment for their patients,” said Dr. Jack Regan, CEO and Founder of LexaGene. “Following the placement at Mass Vet, we will continue placing our devices at various other sites throughout the United States as part of our ongoing beta test program. This will enable potential customers to experience the technology in their own facility so that they can compare LX-generated results to their standard testing methods. We are confident these users will quickly appreciate the benefits of our technology and this will help seed future sales.”

The beta LX prototype is expected to identify the presence of bacteria in the overwhelming majority of urinary tract infections.  In addition, the beta prototype will simultaneously screen samples for common antibiotic resistance factors providing veterinarians the information they need to select the best treatment for their patients.

“Emergency and critical care veterinarians are eagerly awaiting the commercialization of an accurate instrument that can identify the cause of an infection and whether any antibiotic resistance factors are detected.  We are very excited to have the opportunity to first test LexaGene’s technology.  It is amazing that their instrument returns results so quickly, as we are used to waiting 3 days to get results back.  Shortening the turn-around time for quality results will lead to much better patient care,” said Dr. Chand Khanna DVM, PhD, DACVIM (Onc), DACVP (Hon), Chief Science Officer of Ethos Veterinary Health and President of Ethos Discovery.

A video interview with Dr. Jack Regan regarding this news can be viewed here.

We are pleased to announce that LexaGene will host a webinar tomorrow, Thursday, June 6th at 11 AM EST to provide an overview of the Company.  The webinar signup can be accessed at this link.

To be added to the LexaGene email distribution list, please subscribe on the Company website.

 


About LexaGene Holdings Inc.
LexaGene is a biotechnology company that develops genetic analyzers for pathogen detection and other molecular markers for on-site rapid testing in veterinary diagnostics, food safety and for use in open-access markets such as clinical research, agricultural testing and biodefense. End-users simply need to collect a sample, load it onto the instrument with a sample preparation cartridge, and press ‘go’. The LX Analyzer delivers excellent sensitivity, specificity, and breadth of detection and can process multiple samples at a time, in an on-demand fashion, returning results in about 1 hour. The unique open-access feature is designed for custom testing so that end-users can load their own real-time PCR assays onto the instrument to target any genetic target of interest.

About Ethos Veterinary Health
Ethos Veterinary Health is a veterinary health company with hospitals across the U.S. providing advanced medical care for pets. Our approach includes a focus on transformative science, continuous learning and growth for team members, and collaboration. For more information, ethosvet.com.

Media Contacts
Nicole Ridgedale
Director of Corporate Marketing, LexaGene
800.215.1824 ext 206
nridgedale@lexagene.com

Investor Relations
Jay Adelaar
Vice President of Capital Markets, LexaGene
800.215.1824 ext 207
jadelaar@lexagene.com

TGEN-Ethos Study Underscores Need for Setting High Standards in Veterinary Cancer Diagnostics

, , , , ,

Written by Steve Yozwiak

PHOENIX, Ariz. — May 21, 2019 — Ethos Veterinary Health, Ethos Discovery, and the Translational Genomics Research Institute (TGen), an affiliate of City of Hope, announced today that they have developed a highly accurate test for the diagnosis of canine lymphoma.

In a study published in the Journal of Veterinary Internal Medicine (JVIM), Ethos and TGen found that their test, called ePARR, was more than 90 percent accurate among a range of lymphoma sample types (link to the complete JVIM article is below).

TGen conducted genetic analysis of more than 180 dogs with naturally occurring cancer to confirm if they had lymphoma, and then determine exactly what type of lymphoma, which is a common and aggressive cancer in dogs.

“An ongoing need exists for robust validation of molecular diagnostics in veterinary medicine. This study is an example of exhaustive validation of one such molecular test,” said Dr. Will Hendricks, an Assistant Professor in TGen’s Integrated Cancer Genomics Division, and one of the study’s co-senior authors. “Overall, ePARR is more than 90 percent accurate across sample types and diagnostic settings.”

The study authors suggest that such tests could be even more accurate if testing facilities adopted more uniform testing techniques, established uniform high performance standards, and made their results more readily available to the general research community.

“In the veterinary diagnostic area, there is a need for methodological consistency and transparency. Each lab has their own methods for how to run the same test,” said Dr. Chand Khanna, Chief Science Officer of Ethos Veterinary Health, and also a co-senior author of the study. “Our validation of ePARR included over 180 dogs and a broad diversity of sample types, including cell pellets, air dried aspirates, and formalin-fixed paraffin-embedded tissues.”

Shukmei Wong, who is a TGen Senior Research Associate in the Hendricks Laboratory, who conducted the study experiments, and is a co-author of the study, said: “I hope this paper will inspire more reporting of assay methods and metrics, and help drive the creation of reference standards and more consistent protocols in diagnostics in veterinary medicine.”

Dr. Sam Stewart, Science Commercialization Fellow at Ethos Veterinary Health, agrees:

“It is truly unique to see such complete rigorous validation of a molecular assay in this field, and we hope this standard of transparency and quality will be followed by others. As a Critical Care doctor, I am proud to offer this high level of quality in a diagnostic assay to my patients.”

Molecular level investigations into dog DNA could someday not only improve the health of dogs with cancer, but also help contribute to a better understanding of cancer in humans, as well.

This study was funded by non-profit Ethos Discovery, which is evaluating options to make the ePARR test available to veterinarians and pet owners.

The study — Polymerase Chain Reaction for Antigen Receptor Rearrangement (PARR): Benchmarking performance of a lymphoid clonality assay in diverse canine sample types — was published April 2 in the Journal of Veterinary Internal Medicine.

No dogs were harmed during this research. Only tissue samples from pet dogs with naturally occurring cancers were examined.

 

Related Links:

# # #

About Ethos Veterinary Health

Ethos is a veterinary health company with hospitals across the U.S. providing advanced medical care for pets. Our approach includes a focus on transformative science, continuous learning, growth for team members, and the development of collaborative relationships. For more information, visit ethosvet.com.

About Ethos Discovery

Ethos Discovery is a 501(c)(3) non-profit incubator of scientific innovation that seeks to improve health outcomes in pets and humans with complex medical problems, including cancer. For more information, please visit ethosdiscovery.org.

About TGen, an affiliate of City of Hope

Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based non-profit organization dedicated to conducting groundbreaking research with life-changing results. TGen is affiliated with City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases: www.cityofhope.org. This precision medicine affiliation enables both institutes to complement each other in research and patient care, with City of Hope providing a significant clinical setting to advance scientific discoveries made by TGen. TGen is focused on helping patients with neurological disorders, cancer, diabetes and infectious diseases through cutting-edge translational research (the process of rapidly moving research toward patient benefit). TGen physicians and scientists work to unravel the genetic components of both common and complex rare diseases in adults and children. Working with collaborators in the scientific and medical communities worldwide, TGen makes a substantial contribution to help our patients through efficiency and effectiveness of the translational process.

For more information, visit: www.tgen.org. Follow TGen on Facebook, LinkedIn and Twitter @TGen

Media Contact at TGen:
Steve Yozwiak
TGen Senior Science Writer
602-343-8704
syozwiak@tgen.org

AAHA, VetBloom to Launch Exclusive AAHA Member Learning Platform

, , ,

LAKEWOOD, Colorado – April 30, 2019 – In a move that brings a veterinary industry leader in online CE together with the only association to accredit companion animal hospitals in North America, VetBloom and the American Animal Hospital Association (AAHA) are excited to announce the upcoming launch of the AAHA | Learning platform.

Provided as an exclusive AAHA member benefit, the new platform will be powered and hosted by VetBloom, a digital learning ecosystem from Ethos Veterinary Health (Ethos). At launch, it will include access to more than 50 hours of non-sponsored RACE-approved technical CE for veterinarians and technicians. But that’s only the start.

With courses available in a variety of formats ranging from interactive case-based learning modules and virtual simulations to podcasts, webinars, and more, VetBloom sets the industry standard for creating innovative and engaging content using cutting-edge learning technologies. The collaboration will open the door for AAHA to provide its own industry-leading educational resources to more than 4,400 accredited hospitals across Canada and the United States in fresh, relevant, and transformative ways.

“We couldn’t be more thrilled to be working with such an innovative and forward-thinking organization,” says AAHA Chief Executive Officer Michael Cavanaugh, DVM, DABVP (Emeritus). “VetBloom’s overall pedagogical approach combined with their aptitude for applying cutting-edge technologies in an easy-to-use and accessible manner makes them a true leader in the online learning space.”

Additional AAHA | Learning platform benefits include:

  • Continued access to high-quality existing AAHA CE, including AAHA’s guidelines
  • The option to upgrade to a premium-level subscription that provides access to hundreds of hours of CE for veterinarians and technicians as well as state-of-the-art, advanced courses
  • An easy-to-use, mobile-friendly interface and user experience that enables AAHA members to access their CE directly from their AAHA account
  • Customer support directly through the knowledgeable AAHA team

While these benefits will be available when the platform launches, new feature additions will be ongoing and content updates will occur regularly.

“We’re tremendously excited to be partnering with an industry leading organization such as AAHA,” says VetBloom founder and Ethos Chief Knowledge Officer Patrick Welch, DVM, MBA, DACVO. “The AAHA and VetBloom teams share a passion for learning and growth, and this collaboration provides us with the opportunity to develop a learning ecosystem that makes a truly meaningful impact for the veterinary industry.”

The AAHA Learning platform will launch in July.

For more information about the American Animal Hospital Association, visit aaha.org.

###

About AAHA

The American Animal Hospital Association is the only organization that accredits companion animal practices throughout the United States and Canada according to high standards of veterinary care. AAHA-accredited hospitals are recognized among the finest in the industry and are consistently at the forefront of advanced veterinary medicine. Pet owners look for AAHA-accredited hospitals because they value their pet’s health and trust the consistent, expert care provided by the entire healthcare team.

About VetBloom

VetBloom is an innovative learning ecosystem featuring the expertise of the finest veterinary professionals in the industry, along with cutting-edge, online instruction. Team members learn through direct and virtual instruction, interactive case-based scenarios and 3D simulations. VetBloom allows veterinary professionals to advance their skills from anywhere in the world. For more information visit vetbloom.com.

About Ethos

Ethos Veterinary Health is a veterinary health company with hospitals across the U.S. providing advanced medical care for pets. Our approach includes a focus on transformative science, continuous learning and growth for team members and collaboration. For more information, visit ethosvet.com.

First-Ever, Nationwide, Multicenter, Prospective Study of Canine Splenic Hemangiosarcoma

, , ,

Cutting Edge Cancer Research in Veterinary Specialty Practice: Ethos Veterinary Health Completes First-Ever, Nationwide, Multicenter, Prospective Study of Canine Splenic Hemangiosarcoma

Woburn, Mass. — Jan. 15, 2019 — Ethos Veterinary Health (Ethos) has completed the patient accrual phase of their new Canine Hemangiosarcoma Molecular Profiling (CHAMP) study.

Hemangiosarcoma is one of the most malignant forms of cancer in dogs and CHAMP is the first nationwide, multicenter, prospective study of canine splenic hemangiosarcoma, which is a cancer of the blood vessels often affecting the spleen.

“Ethos is proud of this unprecedented milestone and of our investments in innovation that will improve outcomes for our patients,” said Ames Prentiss, CEO of Ethos Veterinary Health.

The clinical description of this population of dogs with splenic tumor rupture, a common diagnosis made on an emergency basis, is expected to be submitted for publication before the end of Q1 2019 by Dr. Sam Stewart, DACVECC and colleagues at Ethos.

“I expect the CHAMP study to change many misperceptions of hemangiosarcoma in the veterinary community, and ultimately help pet owners and veterinarians make better decisions regarding treatment,” said Sam Stewart, DVM, DACVECC, Science Commercialization Fellow at Ethos Veterinary Health.

The study also provided state-of-the-art care to dogs with splenic tumor rupture over a 12-month period and allowed for the collection samples for molecular analysis. CHAMP will result in a molecular characterization of genomic alterations in canine hemangiosarcoma which will help identify dogs with distinct prognoses and potentially life-saving molecularly-targeted therapies. Publication of these genomic data is expected in Q2 2019.

“When viewed from the perspective of a veterinarian trained to treat cancer – I am a veterinary Oncologist – the new genomic analysis of this highly aggressive cancer has already provided an opportunity for me to treat dogs differently,” said Chand Khanna, DVM, PhD, DACVIM (Onc), Chief Science Officer of Ethos Veterinary Health. “We are very excited to now launch clinical trials that will assess these new treatments and change outcomes for dogs with this very aggressive cancer.”

A critical component of this prospective study will be the molecular characterization of the disease recently completed through a collaboration of Ethos and The Translational Genomics Research Institute (TGen), an affiliate of City of Hope. This Ethos-TGen collaboration allowed for the use of advanced next generation sequencing technology of tumor and blood samples collected from the CHAMP dogs.

Will Hendricks, Ph.D., Assistant Professor, Integrated Cancer Genomics Division of TGen, added: “The results of this collaboration between TGen and Ethos will bring needed evidence to the field of molecular and precision medicine. We are not only excited about the application of these data to dogs, but also to human patients with very similar cancers as part of a comparative approach to cancer biology and therapy, so-called comparative oncology.”

These new trials will open through Ethos practices in Q2 2019. In parallel, additional studies are ongoing to develop a molecular diagnostic to help define the prognosis of individual dogs and identify optimal molecularly derived treatments for each patient.

 

# # #

About Ethos Veterinary Health

Ethos is a veterinary health company with hospitals across the U.S. providing advanced medical care for pets. Our approach includes a focus on transformative science, continuous learning and growth for team members and collaboration. For more information, visit ethosvet.com.

About Ethos Discovery

Ethos Discovery is a 501(c)(3) non-profit incubator of scientific innovation that seeks to improve health outcomes in pets and humans with complex medical problems, including cancer. For more information, please visit ethosdiscovery.org.

About TGen, an affiliate of City of Hope

Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based non-profit organization dedicated to conducting groundbreaking research with life changing results. TGen is affiliated with City of Hope, a world-renowned independent research and cancer and diabetes treatment center: www.cityofhope.org. This precision medicine affiliation enables both institutes to complement each other in research and patient care, with City of Hope providing a significant clinical setting to advance scientific discoveries made by TGen. TGen is focused on helping patients with neurological disorders, cancer, diabetes, and infectious diseases, through cutting edge translational research (the process of rapidly moving research towards patient benefit). TGen physicians and scientists work to unravel the genetic components of both common and rare complex diseases in adults and children. Working with collaborators in the scientific and medical communities literally worldwide, TGen makes a substantial contribution to help our patients through efficiency and effectiveness of the translational process. For more information, visit: www.tgen.org.

Ethos Veterinary Health LLC Recapitalization with Brown Brothers Harriman Capital Partners

, ,

Brown Brothers Harriman Completes Investment in Ethos Veterinary Health LLC

New York, NY, JANUARY 9, 2019BBH Capital Partners (“BBHCP”) announced today that it has completed a recapitalization of Ethos Veterinary Health LLC (“Ethos” or the “Company”). Headquartered in Woburn, Massachusetts, Ethos is one of the largest pure-play independent providers of specialty veterinary health services, including 24/7 emergency care, surgical procedures, radiology services and internal medicine. Ethos operates 21 specialty and emergency hospitals and employs over 300 doctors of veterinary medicine. In addition, Ethos provides a complementary suite of reference laboratory and compounding pharmacy services and has developed a well-regarded continuing education and training platform to support the ongoing professional development of its veterinarians and technicians.

Ethos has earned a national reputation among veterinary professionals for providing exceptional quality-of-care, world-class professional development as well as a veterinarian-first culture. After the recapitalization, Ethos remains majority owned by its founders and professionals in the veterinary industry under the leadership of CEO and Co-Founder Ames Prentiss and is well capitalized to further accelerate a growth strategy that will continue to focus on expanding existing hospitals, acquisitions and growth of the complementary suite of services.

[Read More]

About Ethos Veterinary Health

Ethos is a veterinary health company with 17 hospitals across the U.S. providing advanced medical care for pets. Our approach includes a focus on transformative science, continuous learning and growth for team members, and collaboration. For more information, visit ethosvet.com.

About BBH Capital Partners

BBH Capital Partners (“BBHCP”), a private equity strategy of Brown Brothers Harriman & Co., provides friendly capital solutions to growth-oriented middle-market companies. Our flexible investment mandate gives us the ability to act as a control or non-control investor and to structure our investments as a combination of equity and subordinated debt securities as needed. BBHCP typically invests between $30 million and $125 million per platform investment, and our capital is used to support a variety of transactions, including management or leveraged buyouts, growth financings, recapitalizations (including dividend recapitalizations), buy-and-build strategies and acquisitions.

Western Reserve Partners Advises Ethos Veterinary Health

, ,

Western Reserve Partners Advises Ethos Veterinary Health in its Growth Equity Recapitalization

CLEVELAND, OH (December 18, 2018)Western Reserve Partners, a division of Citizens Capital Markets, Inc., is pleased to announce that it served as the exclusive financial advisor to Ethos Veterinary Health, LLC (“Ethos” or the “Company”) in its recapitalization by Brown Brothers Harriman Capital Partners (“BBHCP”). Through the recapitalization, Ethos remains independently owned by its veterinarian professionals and, under the leadership of founding CEO Ames Prentiss, is well capitalized to further accelerate its acquisition-focused growth strategy.

Headquartered in Woburn, Massachusetts, Ethos is a leading provider of specialty veterinary health services with over 300 doctors of veterinary medicine throughout the United States. The Company’s unique integrated clinical model includes 21 specialty & emergency hospitals and a suite of complementary reference laboratory, compounding pharmacy and SaaS-based training services. The Company, formed in 2015 through the merger of four veterinary hospital systems, has since acquired six additional hospital systems and also earned a national reputation among veterinary professionals for providing exceptional quality-of-care, world-class professional development and a veterinarian-first culture. Through this minority equity recapitalization with Brown Brothers Harriman, Ethos has provided liquidity to its owners, gained a partner with significant experience scaling multi-unit healthcare businesses and positioned itself for future organic and acquisitive growth.

[Read More]

About Western Reserve Partners

Western Reserve Partners, a division of Citizens Capital Markets, Inc., provides M&A, capital raising and other financial advisory services to middle market companies across a focused set of industry verticals. We deliver thoughtful advice, keen market insight and superior execution to our clients, both nationally and internationally, and our managing directors average nearly 30 years of experience and have directly executed more than 700 transactions throughout their careers.

Western Reserve Partners is a part of Citizens Financial Group, one of the oldest and largest financial institutions in the U.S. Also, as a member of Oaklins, the world’s most experienced mid-market M&A advisory organization, Western Reserve Partners has unparalleled access to global companies and investors.